Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

RXRX

Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:RXRX
FechaHoraFuenteTítuloSímboloCompañía
28/04/202308:30Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:RXRXRecursion Pharmaceuticals Inc
28/04/202308:28Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:RXRXRecursion Pharmaceuticals Inc
18/04/202315:32Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:RXRXRecursion Pharmaceuticals Inc
06/04/202316:39Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:RXRXRecursion Pharmaceuticals Inc
03/04/202307:30GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
28/03/202315:14GlobeNewswire Inc.Recursion Publishes Second Annual Environmental, Social and Governance ReportNASDAQ:RXRXRecursion Pharmaceuticals Inc
10/03/202315:07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:RXRXRecursion Pharmaceuticals Inc
01/03/202307:00GlobeNewswire Inc.Recursion to Participate in Upcoming Investor ConferencesNASDAQ:RXRXRecursion Pharmaceuticals Inc
27/02/202316:00Edgar (US Regulatory)Annual Report (10-k)NASDAQ:RXRXRecursion Pharmaceuticals Inc
21/02/202310:00GlobeNewswire Inc.Community Leaders Unite to Provide Support and Resources for Thousands of Utahns with Rare DiseasesNASDAQ:RXRXRecursion Pharmaceuticals Inc
14/02/202315:09Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/02/202310:55Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:RXRXRecursion Pharmaceuticals Inc
26/01/202307:30PR Newswire (US)Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D DayNASDAQ:RXRXRecursion Pharmaceuticals Inc
16/11/202205:05TipRanksBerenberg Bank Reaffirms Their Buy Rating on Recursion Pharmaceuticals (RXRX)NASDAQ:RXRXRecursion Pharmaceuticals Inc
09/11/202222:35TipRanksSVB Securities Keeps Their Hold Rating on Recursion Pharmaceuticals (RXRX)NASDAQ:RXRXRecursion Pharmaceuticals Inc
08/11/202215:37Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:RXRXRecursion Pharmaceuticals Inc
08/11/202215:30PR Newswire (US)Recursion Provides Business Updates and Reports Third Quarter 2022 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
25/10/202215:35TipRanksSVB Securities Reaffirms Their Hold Rating on Recursion Pharmaceuticals (RXRX)NASDAQ:RXRXRecursion Pharmaceuticals Inc
25/10/202207:00PR Newswire (US)Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik ABNASDAQ:RXRXRecursion Pharmaceuticals Inc
13/09/202206:59PR Newswire (US)Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022NASDAQ:RXRXRecursion Pharmaceuticals Inc
18/08/202206:55PR Newswire (US)Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability ForumNASDAQ:RXRXRecursion Pharmaceuticals Inc
09/08/202215:15PR Newswire (US)Recursion Provides Business Updates and Reports Second Quarter 2022 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
21/07/202211:15TipRanksBerenberg Bank Thinks Recursion Pharmaceuticals’ Stock is Going to RecoverNASDAQ:RXRXRecursion Pharmaceuticals Inc
21/07/202206:55PR Newswire (US)Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous PolyposisNASDAQ:RXRXRecursion Pharmaceuticals Inc
20/06/202206:55PR Newswire (US)Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF ConferenceNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/05/202207:25TipRanksRecursion Pharmaceuticals (RXRX) Receives a Hold from J.P. MorganNASDAQ:RXRXRecursion Pharmaceuticals Inc
12/05/202202:38TipRanksRecursion Pharmaceuticals (RXRX) Gets a Hold Rating from SVB SecuritiesNASDAQ:RXRXRecursion Pharmaceuticals Inc
10/05/202216:05Edgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:RXRXRecursion Pharmaceuticals Inc
10/05/202215:29PR Newswire (US)Recursion Provides Business Updates and Reports First Quarter 2022 Financial ResultsNASDAQ:RXRXRecursion Pharmaceuticals Inc
11/04/202207:51Dow Jones NewsRecursion Pharma Gets FDA Fast-Track Designation for Polyp TreatmentNASDAQ:RXRXRecursion Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:RXRX